Constipation and bloating: Slowed gut motility can lead to less frequent bowel movements and persistent feelings of fullness or bloating
Combining glucagon-receptor agonism with GLP-1/GIP agonism would seem to work against itself
Recently, Pfizer also successfully secured the ownership of GLP-1 biotechnology company Metsera after a surprise bidding conflict, adding Metseras injectable asset, MET-097i (which is in Phase 2b testing and has the potential for once-a-month dosing), to its portfolio
Unlike subcutaneous fat, visceral fat drains directly into your portal blood circulation, sending inflammatory signals straight to your liver and metabolic organs
Plateau-Breaking Intervention: Provides the vital metabolic surge needed to overcome stubborn weight stalls experienced on lower GLP-1 protocols
doi: 10.1016/j.intimp.2020.106226 44